2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

2:30PM-4:00PM: Abstract Number: 1889

Patterns of Glucocorticoid Use and Provider-Level Variation in a Commercially Insured Incident Rheumatoid Arthritis Population

4M094 ACR/ARHP Abstract: Health Services Research I: Focus on Big Data (1887–1892)

2:30PM-4:00PM: Abstract Number: 1829

Perturbations of the Gut Fungal and Bacterial Microbiome with Biologic Therapy in Spondyloarthritis

4M088 ACR Abstract: Spondyloarthritis Incl PsA–Basic Science (1828–1833)

2:30PM-4:00PM: Abstract Number: 1870

Phase 2 Trial of Induction Therapy with Anti-CD20 (Rituximab) Followed By Maintenance Therapy with Anti-BAFF (Belimumab) in Patients with Active Lupus Nephritis

4M081 ACR Abstract: Edmond L. Dubois, MD Memorial Lecture: SLE–Clinical (1870–1874)

2:30PM-4:00PM: Abstract Number: 1886

Phenotypic Subgroups in IgG4-Related Disease – a Cluster Analysis

4M091 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os I: Population-Based Studies(1881–1886)

2:30PM-4:00PM: Abstract Number: 1851

Physical Function Trajectories in Children with Juvenile Myositis

4M084 ACR Abstract: Pediatric Rheum–Clinical I: Outcomes & Comorbidities (1846–1851)

2:30PM-4:00PM: Abstract Number: 1887

Practice Variation in Prescriptions of Non-TNFi Biologics and Tofacitinib: Data from the Rheumatology Informatics System for Effectiveness (RISE) Registry

4M094 ACR/ARHP Abstract: Health Services Research I: Focus on Big Data (1887–1892)

2:30PM-4:00PM: Abstract Number: 1852

Pregnancy in Lupus: 17-Year U.S. Nationwide Trend in Obstetric and Maternal Outcomes

4M087 ACR Abstract: Reproductive Issues in Rheumatic Disorders (1852–1857)

2:30PM-4:00PM: Abstract Number: 1832

Proteomic and Transcriptomic Profiling of Cells in Ankylosing Spondylitis Patients Identifies a Novel, Synovial-Resident CD8+ T Cell

4M088 ACR Abstract: Spondyloarthritis Incl PsA–Basic Science (1828–1833)

2:30PM-4:00PM: Abstract Number: 1844

Racial Disparities and Accelerated SLE Mortality from a Population-Based Registry: The Georgia Lupus Registry

4M083 ACR Abstract: Healthcare Disparities in Rheumatology (1840–1845)

2:30PM-4:00PM: Abstract Number: 1874

Remission and Low Disease Activity State Are Protective of Intermediate and Long-Term Outcomes in SLE Patients. Data from a Multi-Ethnic, Multi-Center US Cohort

4M081 ACR Abstract: Edmond L. Dubois, MD Memorial Lecture: SLE–Clinical (1870–1874)

2:30PM-4:00PM: Abstract Number: 1849

Remission Status after 18 Years of Follow-up in the Population-Based Nordic Juvenile Idiopathic Arthritis (JIA) Cohort

4M084 ACR Abstract: Pediatric Rheum–Clinical I: Outcomes & Comorbidities (1846–1851)

2:30PM-4:00PM: Abstract Number: 1825

Rheumatoid Arthritis Associated Haploinsufficiency in PTPN2 Enhances Severity of IL-17 Mediated Autoimmune Arthritis

4M085 ACR Abstract: RA–Animal Models (1822–1827)

2:30PM-4:00PM: Abstract Number: 1822

RNA-Sequencing of Mouse and Human Synovial Fibroblasts Reveals Fibroblast Subset-Specific Responses to Inflammation

4M085 ACR Abstract: RA–Animal Models (1822–1827)

2:30PM-4:00PM: Abstract Number: 1830

Role of BMP2 in Entheseal Bone Formation in Inflammatory Arthritis

4M088 ACR Abstract: Spondyloarthritis Incl PsA–Basic Science (1828–1833)

2:30PM-4:00PM: Abstract Number: 1872

Safety and Efficacy of Allogeneic Umbilical Cord-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus: Results of an Open-Label Phase I Study

4M081 ACR Abstract: Edmond L. Dubois, MD Memorial Lecture: SLE–Clinical (1870–1874)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].